Heterozygous loss-of-function mutations in progranulin (GRN) cause frontotemporal
dementia (FTD), a leading cause of early-onset dementia characterized clinically by
behavioral, social, and language deficits. There are currently no FDA-approved therapeutics
for FTD-GRN, but this has been an active area of investigation, and several approaches are
now in clinical trials. Here, we review preclinical development of therapies for FTD-GRN with
a focus on testing in mouse models. Since most FTD-GRN-associated mutations cause …